Target intelligence / Profile preview

Ovalbumin-specific CD8+ T-cell receptor (recognizing SIINFEKL-H-2Kb) (OT-I TCR)

Target
OT-I TCR
Molecular classification
T-cell receptor, Heterodimeric protein, Antigen-specific receptor, Receptor
01

Overview

The Ovalbumin-specific CD8+ T-cell receptor (OT-I TCR) is a well-characterized heterodimeric receptor that specifically recognizes the SIINFEKL peptide (residues 257-264 of chicken ovalbumin) when presented by the murine MHC class I molecule H-2Kb (Hogquist et al., 1994, Cell). It serves as a gold-standard model in immunology for studying CD8+ T-cell biology, including development, activation, and effector functions (Curtsinger et al., 1999, J Immunol). In research, the OT-I TCR is frequently utilized in transgenic mouse models to evaluate the efficacy of vaccines, cancer immunotherapies, and the mechanisms of T-cell exhaustion (Zehn et al., 2009, Nature). The interaction between the TCR and the SIINFEKL-H-2Kb complex triggers intracellular signaling via the CD3 complex, leading to the secretion of pro-inflammatory cytokines like IFN-gamma and the release of cytotoxic granules (Rosette et al., 2001, Immunity). While primarily an experimental tool, it provides critical insights into the design of TCR-engineered T-cell therapies for human diseases. Its high affinity and specificity make it an ideal system for testing novel drug delivery systems and antigen-presentation platforms. The receptor is composed of Vα2 and Vβ5 chains, which define its unique specificity (UniProt). It is often used in adoptive cell transfer experiments to track the fate of antigen-specific T cells in vivo. This system has been instrumental in defining the requirements for T-cell activation and tolerance.

Other names
OT-I T-cell receptorSIINFEKL-specific TCROVA257-264-specific TCRVα2Vβ5 T-cell receptorOvalbumin-specific CD8+ T-cell receptor
02

Mechanism of action

The OT-I TCR recognizes the SIINFEKL peptide presented by the H-2Kb MHC class I molecule, initiating a signaling cascade through the CD3 complex that leads to T-cell activation, proliferation, and the production of cytotoxic molecules like perforin and granzymes (Rosette et al., 2001, Immunity).

03

Biological functions

Immune responseAntigen recognitionT-cell activationCytotoxicitySignal transduction
04

Disease associations

CancerInfectionAutoimmunity
05

Safety considerations

Off-target reactivityCytokine release syndromeOn-target off-tumor toxicity in therapeutic models
06

Interacting drugs

SIINFEKL peptide

3 more in the full profile.

07

Biomarkers

SIINFEKL-H-2Kb tetramer bindingCD69CD25Interferon-gammaGranzyme B

Beyond the preview

Go deeper on Ovalbumin-specific CD8+ T-cell receptor (recognizing SIINFEKL-H-2Kb) (OT-I TCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ovalbumin-specific CD8+ T-cell receptor (recognizing SIINFEKL-H-2Kb) (OT-I TCR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call